Zheng Ziyao, Ke Liyuan, Ye Shumin, Shi Peiying, Yao Hong
Department of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People's Republic of China.
Department of Traditional Chinese Medicine Resource and Bee Products, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, 350002, People's Republic of China.
Drug Des Devel Ther. 2024 Dec 15;18:6031-6060. doi: 10.2147/DDDT.S494555. eCollection 2024.
Cryptotanshinone (CTS) is an important active ingredient of Bge. In recent years, its remarkable pharmacological effects have triggered extensive and in-depth studies. The aim of this study is to retrieve the latest research progress on CTS and provide prospects for future research. The selection of literature for inclusion, data extraction and methodological quality assessment were discussed. Studies included (1) physicochemical and ADME/Tox properties, (2) pharmacological effects and mechanism, (3) conclusion and bioinformatics analysis. A total of 915 titles and abstracts were screened, resulting in 184 papers used in this review; CTS has shown therapeutic effects on a variety of diseases by modulating multiple molecular pathways. For example, CTS primarily targets NF-κB pathway and MAPK pathway to have a therapeutic role in cardiovascular diseases; in cancer, CTS shows superior efficacy through the PI3K/Akt/mTOR pathway and the JAK/STAT pathway; CTS act on the Nrf2/HO-1 pathway to combat neurological diseases. In addition, key targets of CTS were predicted by bioinformatics analysis, referring to disease ontology (DO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene ontology (GO) enrichment analysis, with R Studio; AKT1, MAPK1, STAT3, P53 and EGFR are predicted to be the key targets of CTS against diseases. The key proteins were then docked by Autodock software to preliminarily assess their binding activities. This review provided new insights into research of CTS and its potential applications in the future, and especially the targets and directly binding modes for CTS are waiting to be investigated.
隐丹参酮（CTS）是丹参的一种重要活性成分。近年来，其显著的药理作用引发了广泛而深入的研究。本研究旨在检索CTS的最新研究进展，并为未来研究提供展望。讨论了纳入文献的选择、数据提取和方法学质量评估。研究内容包括：（1）理化性质及ADME/Tox特性；（2）药理作用及机制；（3）结论及生物信息学分析。共筛选了915篇标题和摘要，最终184篇论文用于本综述；CTS通过调节多种分子途径对多种疾病显示出治疗作用。例如，CTS主要靶向NF-κB途径和MAPK途径，对心血管疾病发挥治疗作用；在癌症中，CTS通过PI3K/Akt/mTOR途径和JAK/STAT途径显示出卓越疗效；CTS作用于Nrf2/HO-1途径以对抗神经疾病。此外，通过生物信息学分析预测了CTS的关键靶点，参考疾病本体论（DO）、京都基因与基因组百科全书（KEGG）和基因本体论（GO）富集分析，使用R Studio；预测AKT1、MAPK1、STAT3、P53和EGFR是CTS对抗疾病的关键靶点。然后通过Autodock软件对关键蛋白进行对接，初步评估它们的结合活性。本综述为CTS的研究及其未来潜在应用提供了新的见解，尤其是CTS的靶点和直接结合模式有待进一步研究。
